Kristiina Vuori MD - 07 Dec 2021 Form 4 Insider Report for Inhibrx, Inc.

Role
Director
Signature
/s/ Kelly D. Deck, attorney-in-fact
Issuer symbol
N/A
Transactions as of
07 Dec 2021
Net transactions value
$0
Form type
4
Filing time
07 Dec 2021, 18:43:02 UTC
Previous filing
29 Oct 2021
Next filing
18 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INBX Stock Option (right to buy) Award $0 +30,000 $0.000000 30,000 07 Dec 2021 Common Stock 30,000 $40.45 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on December 7, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.